{"version":"1.0","provider_name":"Grau &amp; Angulo Abogados","provider_url":"https:\/\/ga-ip.com\/en\/","author_name":"Grau &amp; Angulo Abogados","author_url":"https:\/\/ga-ip.com\/en\/author\/admin_gba\/","title":"Barcelona patent court upholds valsartan-amlodipine patent invalidity - Grau &amp; Angulo Abogados","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"Qnfs6iFyta\"><a href=\"https:\/\/ga-ip.com\/en\/barcelona-patent-court-upholds-valsartanamlodipine-patent-invalidity\/\">Barcelona patent court upholds valsartan-amlodipine patent invalidity<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/ga-ip.com\/en\/barcelona-patent-court-upholds-valsartanamlodipine-patent-invalidity\/embed\/#?secret=Qnfs6iFyta\" width=\"600\" height=\"338\" title=\"&#8220;Barcelona patent court upholds valsartan-amlodipine patent invalidity&#8221; &#8212; Grau &amp; Angulo Abogados\" data-secret=\"Qnfs6iFyta\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/ga-ip.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/ga-ip.com\/wp-content\/uploads\/2018\/06\/nuria.jpg","thumbnail_width":713,"thumbnail_height":425,"description":"On 14 March 2018 the Barcelona Commercial Court Number 4 dismissed a patent infringement action brought by Novartis against the first generics in Spain of its valsartan and amlodipine medicinal product for the treatment of hypertension (Exforge). The court upheld the defendants' counterclaim for invalidity of the asserted patent."}